Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey

dc.contributor.authorCanonica G Walter
dc.contributor.authorKlimek Ludger
dc.contributor.authorAcaster Sarah
dc.contributor.authorDollner Ralph
dc.contributor.authorKaulsay Ranbir
dc.contributor.authorLo Siu Hing
dc.contributor.authorPrice David B
dc.contributor.authorScadding Glenis K
dc.contributor.authorValovirta Erkka
dc.contributor.authorZieglmayer Petra
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organization-code1.2.246.10.2458963.20.61334543354
dc.converis.publication-id56055729
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/56055729
dc.date.accessioned2022-10-28T13:46:30Z
dc.date.available2022-10-28T13:46:30Z
dc.description.abstract<p><strong>Objective</strong><br></p><p><strong></strong>The aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the patient perspective, (2) investigate MP-AzeFlu use in real life and its impact on patients' lives and (3) explore factors associated with treatment satisfaction.<br></p><p><strong>Methods</strong><br></p><p><strong></strong>A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven European countries (March-June 2019). Questions explored AR burden and treatment satisfaction. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM-9; max score = 100). Participants (aged >= 18 years) had a doctor/healthcare provider confirmed AR diagnosis and used MP-AzeFlu within the last year.<br></p><p><strong>Results</strong><br></p><p>Pre-MP-AzeFlu treatment, participants (n = 1004) reported an average of 3.3 (SD:3.5) doctor visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR. Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of participants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy. Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively. 70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s), and >= 70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0 (SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were significantly improved when MP-AzeFlu was taken as recommended.<br></p><p><strong>Conclusions</strong><br></p><p>The impact of AR on patients' lives remains high. Real-life use of MP-AzeFlu reduces that impact and is associated with a high level of effectiveness, convenience and global satisfaction.<br></p>
dc.format.pagerange1259
dc.format.pagerange1272
dc.identifier.eissn1473-4877
dc.identifier.jour-issn0300-7995
dc.identifier.olddbid184230
dc.identifier.oldhandle10024/167324
dc.identifier.urihttps://www.utupub.fi/handle/11111/44263
dc.identifier.urlhttps://www.tandfonline.com/doi/full/10.1080/03007995.2021.1911973
dc.identifier.urnURN:NBN:fi-fe2021093048770
dc.language.isoen
dc.okm.affiliatedauthorValovirta, Erkka
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherTAYLOR & FRANCIS LTD
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1080/03007995.2021.1911973
dc.relation.ispartofjournalCurrent Medical Research and Opinion
dc.relation.issue7
dc.relation.volume37
dc.source.identifierhttps://www.utupub.fi/handle/10024/167324
dc.titleBurden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Burden of allergic rhinitis and impact of MP AzeFlu from the patient perspective pan European patient survey.pdf
Size:
2.44 MB
Format:
Adobe Portable Document Format
Description:
Publisher's version